MLTX MoonLake Immunotherapeutics Insider Trading

CEO Santos da Silva Jorge sold 150,000 MLTX shares in 2 transactions (April 10–13, 2026) for $2.75M at blended $18.35, reducing stake 4.9% amid unprofitable operations.

Santos da Silva Jorge, CEO of MoonLake Immunotherapeutics, executed 2 separate sales totaling 150,000 shares for $2,752,162.86 at an average price of $18.35 per share. The company posted a net loss of $69,729,000 in its most recent full fiscal year, and the stock trades at $18.78 current price—down 69.7% from its 52-week high of $61.99. His prior sales at MLTX show mixed timing: 3 of 5 prior sells were well-timed at the 90-day mark, but his two most recent MLTX sales (December 2025) showed divergent outcomes, with 90-day returns of +26.4% and +20.4% respectively, indicating those recent sales were not well-timed. The current sale reduces his post-transaction holdings to 2,924,893 shares from 3,074,893 shares, retaining a substantial stake despite the disposal.

CFO Bodenstedt sells 87.8K shares (87,795) over 2 days for $1.7M, continuing a pattern of well-timed sells at MLTX

Matthias Bodenstedt (CFO) executed 2 separate sales totaling 87,795 shares for $1,663,934.55, reducing his post-transaction holdings to 1,188,510 shares (-6.9% from prior holdings of 1,276,305). The sales at $18.94 and $19.51 occurred as the stock trades at $17.96, down 71.0% from its 52-week high of $61.99. Critically, Bodenstedt's prior 2 sales at MLTX (2023-12-20 and 2023-12-19) achieved a 90-day well-timed rate of 100%, with the stock declining 13.3% and 18.0% respectively after those sales. The current sale follows this established pattern at a ticker where the company remains unprofitable (net income: $-69,729,000). The timing signal is significant: across his SAME-TICKER HISTORY at MLTX, all 3 prior trades have been well-timed, and the company's fundamentals remain challenged. While the current stock price has risen 0.7% in the past 30 days, the 90-day outcome (which would include the window during which CFO conviction is typically measurable) remains to be seen.

BVF Partners L P/IL sells 3,750,000 shares (78.3% of holdings) at $16.79; stock down 72% from 52-wk high, company unprofitable.

BVF Partners L P/IL filed a Form 4 reporting 3 separate sales totaling 3,750,000 shares for $62,962,500.00 at $16.79 per share on 2026-03-31, reducing its position from 4,789,238 to 1,039,238 shares (a -78.3% reduction). The current price of $17.36 is -72.0% from the 52-week high of $61.99, indicating substantial deterioration in valuation since the insider's entry. The underlying company reported a full-year net income of $-69,729,000.00, confirming unprofitability in its most recent fiscal year. At this same ticker, the insider's prior 3 sales (2024-10-04) all underperformed with a 0 of 3 well-timed rate at the 90-day mark, though this current filing's outcome remains to be observed. The magnitude of the share reduction and the stock's proximity to multi-year lows warrant close monitoring of subsequent company filings and guidance to assess whether this transaction reflects a reassessment of fundamentals.

CEO Jorge sells 200,000 shares for $2,974,700.00; prior 5 MLTX trades all declined 90d post-sale; stock down 76.4% from 52-week high.

Santos da Silva Jorge (Chief Executive Officer) executed 2 separate sales totaling 200,000 shares for $2,974,700.00 on 2025-12-08 and 2025-12-09, reducing his holdings from 3,078,577 shares to 2,878,577 shares (-6.5%). This transaction occurs while MoonLake's stock has fallen 73.1% over 90 days and 76.4% from its 52-week high of $61.99, trading at $14.61 (current). The CEO's timing pattern is stark: across his 5 prior sales at MLTX, all were followed by 90-day declines ranging from 24.2% to 32.7%, establishing a 100% accuracy rate at timing exits before further deterioration. The company remains unprofitable, with net income of $-69,729,000.00 over its most recent fiscal year. Combined with the stock's extreme recent weakness and the CEO's consistent track record of exiting MLTX before subsequent 90-day losses, this sale warrants scrutiny of whether near-term catalysts may pose further downside risk.

CSO Reich Kristian sold 202,908 shares (100% of holdings) for $3,012,462.44, exiting position entirely as stock tumbles 76.4% from 52-week high.

Reich Kristian, Chief Scientific Officer, executed two separate sales totaling 202.9K shares for $3.0M, completely liquidating his stake at an average price of $14.85. This comes as MLTX trades 76.4% below its 52-week high of $61.99 and amid a -73.1% decline over the past 90 days, despite a +35.0% rebound in the last 30 days. Notably, Reich's cross-ticker track record shows a 100.00% well-timed rate on 14 prior sells with an average 90-day return of -30.2%, and all 5 of his prior MLTX sells were also well-timed at the 90-day mark. The complete divestiture by a CSO of an unprofitable company (net income -$69.7M) following a sustained price collapse raises questions about insider perspective on near-term prospects.

CFO Bodenstedt buys 10.9K shares of MLTX at $9.09 amid -84.9% 52-week decline, unprofitable financials

Chief Financial Officer Matthias Bodenstedt purchased 10,870 shares at $9.09 on 2025-10-08, expanding his holdings from 616,666 to 627,536 shares. The purchase occurs at $9.09 while the current price is $9.38, but critically the stock has collapsed 84.9% from its 52-week high of $61.99 and declined 83.5% over the prior 30 days. MoonLake Immunotherapeutics reported a net loss of $55.2M on a $494.3M market cap, indicating severe unprofitability. While Bodenstedt's cross-ticker track record shows 100% well-timed sells at the 90-day mark, his same-ticker history at MLTX (two sells in December 2023, both well-timed on the downside) and the current fundamental distress suggest this insider purchase occurs in a deeply challenged context rather than a value-recognition signal.

Insider Chen Bihua sells 6,499,978 shares for $46,868,184 as MLTX stock has declined 88.6% from 52-week high

Chen Bihua executed 5 separate sales totaling 6,499,978 shares for $46,868,184.10 on 2025-09-29 and 2025-09-30, reducing holdings by 76.5% to 1,994,173 shares post-transaction. The sales occurred at prices ranging from $6.61 to $9.38, with a blended average of $7.21, while the current price stands at $7.06. The stock has collapsed 88.6% from its 52-week high of $61.99 and declined 87.3% over the prior 30 days. MoonLake is unprofitable, reporting a net loss of $55,220,000 for the most recent fiscal year. The insider's same-ticker history shows a 90-day timing pattern of 4 of 5 prior buys yielding positive 90-day returns, suggesting prior purchase discipline at this ticker; however, this massive liquidation occurs in a severely depressed price environment, well below prior transaction prices and following an extended decline over the filing period.

Director Moukheibir sells entire 23.5K MLTX holding for $1.1M at $48.79; post-sale zero position

Catherine Moukheibir, a director at MoonLake Immunotherapeutics, sold 23,500 shares on 2025-07-03 at $48.79 per share, completely liquidating her holdings and leaving zero shares post-transaction. The sale occurred when MLTX was trading below its 52-week high of $56.30 (current price $47.50 is -15.6% from that high), though the stock has appreciated +44.7% over the past 90 days. The full liquidation of a director's entire position is a notable signal, particularly given that the company reported negative net income of $-39,944,000.00 over its most recent full fiscal year. An investor should monitor whether this complete exit by a board member reflects changed assessments of company fundamentals or future prospects.

Director Sturge Simon sold 171,000 shares of MLTX at $53.72 ($9.2M) on 2024-10-04, reducing holdings by 49.9% while company unprofitable at -$24.3M net income.

Sturge Simon executed a substantial sale of 171,000 shares—exactly half his pre-transaction position of 342,980 shares—at $53.72, raising $9,186,120.00. This divestiture is material in size and represents a significant reduction in his equity stake in MLTX. The timing coincides with stock trading near its 52-week high ($63.86), though 21.9% below peak; the company remains unprofitable with full-year net income of -$24,267,012.00 against a market cap of $2,627,150,383.35. The magnitude and precision of the 50% stake reduction warrants investor attention to whether this reflects fundamental concerns about the company's path to profitability or portfolio rebalancing unrelated to operational outlook.

Director BVF Partners sold 2,000,000 shares ($100.0M) at $50.00; retains 1,287,768 shares post-sale

BVF Partners L P/IL, a director, executed 3 separate sales totaling 2,000,000 shares for $100,003,200.00 at $50.00 on 2024-10-04, reducing holdings by -60.8% from 3,287,768 to 1,287,768 shares. The company is unprofitable (net income $-24,267,012.00 over its most recent full fiscal year), and this substantial single-day liquidation of majority holdings occurs while the stock is -21.9% from its 52-week high of $63.86. The insider's cross-ticker track record shows a poor sell-timing pattern with 0.00% 90d well-timed rate across prior sales, indicating prior dispositions were followed by continued stock appreciation rather than declines. The magnitude and composition of this sale—a near-total reduction in director-level equity stake during a period of operating losses and elevated valuation distance from recent peaks—merit investor attention to the dynamics that prompted such a substantial equity reduction.